{"id":62252,"date":"2026-02-19T05:29:00","date_gmt":"2026-02-18T23:59:00","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/02\/19\/stonegate-updates-coverage-on-incannex-healthcare-inc-ixhl-2q-2026\/"},"modified":"2026-02-19T05:29:00","modified_gmt":"2026-02-18T23:59:00","slug":"stonegate-updates-coverage-on-incannex-healthcare-inc-ixhl-2q-2026","status":"publish","type":"post","link":"https:\/\/new.matribhumisamachar.com\/en\/2026\/02\/19\/stonegate-updates-coverage-on-incannex-healthcare-inc-ixhl-2q-2026\/","title":{"rendered":"Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026"},"content":{"rendered":"<p style=\"text-align: justify;\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/284430\/511\" width=\"2\" height=\"2\" \/><\/p>\n<p style=\"text-align: justify;\">Dallas, Texas&#8211;(Newsfile Corp. &#8211; February 18, 2026) &#8211; Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both low and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm. Exit interviews showed 57.6% of participants reported perceived improvement in their OSA, and most of those described the change as meaningful to daily life. IHL-42X was well tolerated across both dose cohorts, reinforcing its potential for broad use.<\/p>\n<p style=\"text-align: justify;\">To view the full announcement, including downloadable images, bios, and more, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/ej0B0fM8nA\">click here<\/a>.<\/p>\n<p style=\"text-align: justify;\"><b>Key Takeaways:<\/b><\/p>\n<ul style=\"text-align: justify;\">\n<li>IHL-42X receives fast track approval<\/li>\n<li>$68.9M in reported cash &amp; cash equivalents<\/li>\n<li>Positive Phase 2 results for PSX-001<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/api.newsfilecorp.com\/redirect\/87DJDiO4L8\"><img decoding=\"async\" src=\"https:\/\/images.newsfilecorp.com\/files\/7294\/284430_figure1_550.jpg\" alt=\"Cannot view this image? Visit: https:\/\/images.newsfilecorp.com\/files\/7294\/284430_figure1_550.jpg\" \/><\/a><\/p>\n<p style=\"text-align: justify;\"><i>Click image above to view full announcement.<\/i><\/p>\n<hr \/>\n<p style=\"text-align: justify;\"><strong>About Stonegate<\/strong><br \/>\nStonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.<\/p>\n<div style=\"text-align: justify;\">\n<p><b>Contacts:<\/b><\/p>\n<p>Stonegate Capital Partners<br \/>\n(214) 987-4121<br \/>\n<a href=\"mailto:info@stonegateinc.com\">info@stonegateinc.com<\/a><\/p>\n<\/div>\n<p style=\"text-align: justify;\">Source: <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/y4K8KuboAx\">Stonegate, Inc.<\/a><\/p>\n<p style=\"text-align: justify;\">To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/1KYDYTRN0K\">https:\/\/www.newsfilecorp.com\/release\/284430<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dallas, Texas&#8211;(Newsfile Corp. &#8211; February 18, 2026) &#8211; Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both low and high-dose [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":106422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[54732],"tags":[],"class_list":["post-62252","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases"],"_links":{"self":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/62252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=62252"}],"version-history":[{"count":0,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/62252\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media\/106422"}],"wp:attachment":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=62252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=62252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=62252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}